Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s):  LBLTF

Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.


TSXV:LBL.H - Post by User

Comment by Nomoreshells4meon Aug 18, 2020 2:37pm
168 Views
Post# 31424146

RE:RE:RE:RE:RE:RE:RE:News out. Good to go now.

RE:RE:RE:RE:RE:RE:RE:News out. Good to go now.
I couldn't agree with you more, Boobah. The March 17th announcement of the study of Amnioboost for ARDS in COVID-19 patients brought everyone to the yard. The only saving grace now is if the FDA approves a phase 2 trial. In the absence of that announcement. The only thing that could keep some life in this would be an announcement that the Amnioboost for psoriasis trial has been approved by the FDA for phase 2. If the next news release is anything like May 11th. God help us shareholders.
<< Previous
Bullboard Posts
Next >>